NANOG and fragile X syndrome: Figure 5 shows a representative example of immunostaining for Nanog, Oct4 and Sox 2 pluripotency markers as well as FMRP in iPSC lines derived from healthy individuals and FXS patients. The results from all cell lines in this study demonstrated pluripotency marker expression in over 95% of cells (Figure 5D). Control iPSCs showed FMRP expression, while FXS iPSCs did not. Detailed data for all cell iPSC lines are presented in Supplementary Figure S2.